Metronomic therapy for breast cancer

Current Oncology Reports

Volumn 6, Issue 1, 2004, Pages 49-52

  Kaur, Hanspreet ^a   Budd, G Thomas ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; METHOTREXATE; NEUTRALIZING ANTIBODY; PACLITAXEL; TAXANE DERIVATIVE; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VINBLASTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE; CELL KILLING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; DRUG TOXICITY; ENDOTHELIUM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GROWTH INHIBITION; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MOUSE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; REVIEW; SKIN TOXICITY; STOMATITIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 2942578749     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-996-0009-5     Document Type: Review

References (25)

1. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
4. Weidner N, Semple J, Welch W, et al.: Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 1991, 324:1-8.
5. Browder T, Butterfield CE, Kraling BM, et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
6. Stoler DL, Chen N, Basik M, et al.: The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A 1999, 96:15121-15126.
7. Folkman J, Hahnfeldt P, Hlatky L: Cancer: looking outside the genome. Nature Rev Mol Cell Biol 2000, 1:76-79.
8. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 12:31-36.
9. Crawford J, Ozer H, Stoller R, et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991, 325:164-170.
10. Kaban LB, Mulliken JB, Ezekowitz RA, et al.: Antiangiogenic therapy of recurrent giant cell tumor of the mandible with interferon alpha-2a. Pediatrics 1999, 103:1145-1149.
11. Eberhard A, Kahlert S, Goede V, et al.: Heterogeneity of angiogenesis and blood vessel maturation in human tumor: implications for antiangiogenic tumor therapies. Cancer Res 2000, 60:1388-1393.
12. Miller KD, Sweeney CJ, Sledge GW: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195-1206.
13. Gately S, Kerbel R: Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001, 7:427-436.
14. Klement G, Baruchel S, Rak J, et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24.
15. Wild R, Ghosh K, Dings R, et al.: Carboplatin differentially induces the VEGF stress response in endothelial cells: potentiation of anti-tumor effects by combination therapy with antibody to VEGF [abstract]. Proc Am Assoc Cancer Res 2000, 40:307.
16. Shan M, Bocci G, Francia G, et al.: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002, 62:2731-2735.
17. Klement G, Huang P, Mayer B, et al.: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGF-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002, 8:221-232.
18. Engelsman E, Klijn J, Rubens R, et al.: 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer, 1991, 27:966-970.
19. Lopes N, Adams E, Pitts T, et al.: Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993, 32:235-242.
20. Seidman A, Hudis C, Albanel J, et al.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16:3353-3361.
21. Green M, Buzdar A, Smith T, et al.: Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete response rates when compared to every 3-week paclitaxel therapy followed by FAC: final results of a prospective phase III randomized trial [abstract]. Proc ASCO 2002, 21:35a.
22. Burstein H, Manola J, Younger J, et al.: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18:1212-1219.
23. Sedky L, El-Dine I, Hashem B, et al.: Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study [abstract]. Proc ASCO 2002, 21:505a.
24. Colleoni M, Rocca A, Sandri T, et al.: Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2001, 12:73-80.
25. Ellis GK, Livingston RB, Gralow JR, et al.: Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002, 20:3637-3643.